Immunocore Holdings plc (FRA:6YG)
Germany · Delayed Price · Currency is EUR 31.40
0.00 (0.00%)
At close: Aug 26, 2026
Immunocore Holdings Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 430.78 | 400.02 | 310.2 | 249.43 | 174.36 | 36.48 |
| 430.78 | 400.02 | 310.2 | 249.43 | 174.36 | 36.48 | |
Revenue Growth | 20.95% | 28.95% | 24.37% | 43.05% | 377.91% | -11.26% |
Cost of Revenue | 289.19 | 279.96 | 224.88 | 164.58 | 6.4 | 100.25 |
Gross Profit | 141.59 | 120.06 | 85.32 | 84.85 | 167.96 | -63.76 |
Selling, General & Admin | 164.16 | 165.41 | 155.78 | 144.5 | 123.06 | 110.82 |
Research & Development | - | - | - | - | 96.61 | - |
Other Operating Expenses | -19.73 | -19.73 | -18.05 | 0.9 | -0.01 | 0.07 |
Operating Expenses | 144.44 | 145.69 | 137.73 | 145.39 | 219.66 | 110.9 |
Operating Income | -2.85 | -25.63 | -52.41 | -60.55 | -51.7 | -174.66 |
Interest Expense | -12.21 | -12.17 | -18.84 | -5.15 | -5.41 | -5.57 |
Interest & Investment Income | 15.03 | 16.48 | 25.62 | 17.99 | 3.76 | 0.07 |
Currency Exchange Gain (Loss) | 2.61 | 2.22 | -3.45 | -13.18 | 14.16 | 0.29 |
EBT Excluding Unusual Items | 2.58 | -19.1 | -49.08 | -60.89 | -39.2 | -179.88 |
Gain (Loss) on Sale of Investments | -5.32 | - | - | - | - | - |
Other Unusual Items | - | - | -3.85 | - | -1.69 | - |
Pretax Income | -2.73 | -19.1 | -52.94 | -60.89 | -40.88 | -179.88 |
Income Tax Expense | 15.34 | 16.41 | -1.85 | -5.6 | 11.66 | 0.15 |
Net Income | -18.07 | -35.51 | -51.09 | -55.29 | -52.54 | -180.03 |
Net Income to Common | -18.07 | -35.51 | -51.09 | -55.29 | -52.54 | -180.03 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 51 | 50 | 50 | 49 | 46 | 42 |
Shares Outstanding (Diluted) | 51 | 50 | 50 | 49 | 46 | 42 |
Shares Change | 1.14% | 0.71% | 2.25% | 6.94% | 7.59% | 60.19% |
EPS (Basic) | -0.36 | -0.71 | -1.02 | -1.13 | -1.15 | -4.24 |
EPS (Diluted) | -0.36 | -0.71 | -1.02 | -1.13 | -1.15 | -4.24 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -41.15 | -15.05 | 20.89 | -2.49 | -51.41 | -144.49 |
Free Cash Flow Per Share | -0.81 | -0.30 | 0.42 | -0.05 | -1.13 | -3.40 |
Gross Margin | 32.87% | 30.01% | 27.51% | 34.02% | 96.33% | -174.77% |
Operating Margin | -0.66% | -6.41% | -16.89% | -24.27% | -29.65% | -478.73% |
Profit Margin | -4.20% | -8.88% | -16.47% | -22.17% | -30.14% | -493.45% |
Free Cash Flow Margin | -9.55% | -3.76% | 6.73% | -1.00% | -29.49% | -396.04% |
EBITDA | 0.76 | -22.36 | -48.21 | -56.46 | -46.37 | -167.07 |
EBITDA Margin | 0.18% | -5.59% | -15.54% | -22.63% | -26.59% | - |
D&A For EBITDA | 3.61 | 3.27 | 4.2 | 4.09 | 5.34 | 7.59 |
EBIT | -2.85 | -25.63 | -52.41 | -60.55 | -51.7 | -174.66 |
EBIT Margin | -0.66% | -6.41% | -16.89% | -24.27% | -29.65% | - |
Revenue as Reported | 430.78 | 400.02 | 310.2 | 249.43 | 174.36 | 36.48 |